| Name | Title | Contact Details |
|---|
ITM Isotopen Technologien München AG and its subsidiaries develop, produce and supply innovative diagnostic and therapeutic radionuclides and radiopharmaceuticals.
Accumulus Synergy is a global, non-profit organization that is developing a transformative data exchange platform that aims to enable enhanced collaboration and efficiency between life sciences organizations and global health authorities, while also affording users the ability to extract dynamic, data-driven insights from knowledge management. Sponsored by leading biopharmaceutical companies, Accumulus Synergy was formed in 2020 to create innovative solutions that can reduce regulatory review times and transform global data exchange. The non-profit company is creating a first-of-its-kind cloud-based platform between the biopharmaceutical industry and health authorities worldwide. The single-platform approach aims to improve speed, transparencies and efficiencies in the regulatory process by leveraging advanced technology and tools for data exchange. This will help reduce the cost of innovation and ultimately bring patients safe and effective medicines faster.
Meda is a Somerset, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sun Pharma is the world`s fourth largest specialty generic pharmaceutical company and India`s top pharmaceutical company. A vertically integrated business, economies of scale and an extremely skilled team enable us to deliver quality products in a timely manner at affordable prices. It provides high-quality, affordable medicines trusted by customers and patients in over 150 countries across the world. Sun Pharma`s global presence is supported by 50 manufacturing facilities spread across 5 continents, R&D centres across the globe and a multi-cultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising about 2,000 scientists and R&D investments of over 7% of annual revenues.
Carl Greenblatt founded G&W Laboratories, Inc. in 1919 upon his return from military service as a pharmacist with US forces in World War I. While establishing a reputation as an innovative specialist in suppository dosage forms, Carl guided G&W Laboratories with an uncompromising commitment to product integrity and customer service. In 1945, Carl’s son, Burton, also a registered pharmacist, returned from military service in World War II and joined the small but growing company. During the post-war years, G&W expanded its product line beyond suppositories, into creams, ointments, gels and liquids. G&W moved to a larger state-of-the-art laboratory and production facility, which now exceeds 180,000 square feet in South Plainfield, New Jersey. Continuing the high ethical standards and customer focus established by Carl and his son Burton Greenblatt, G&W is still family owned and operated. Burton’s son, Ronald, who joined the company in 1978 and now serves as Chief Executive Officer; and Ronald’s son, Aaron, who joined the company in 2009 after earning his Pharm.D. In addition to strong family ties the family hired Kurt Orlofski, who joined G&W as President and Chief Operating Officer in 2009.